Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In the combined repeat-dose/developmental screening study, unspecific toxic effects have been observed in females at the highest dose tested. No toxicological relevant adverse effects were observed in male rats.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 250 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
The toxic effects on Sprague Dawley rats of both sexes after repeated dosing with the substance, as well as any effects of the test item on male and female reproductive performance, such as gonadal function, conception, parturition and early lactation of the offspring, were investigated. A 3-week treatment-free period was allowed in order to assess recovery from any delayed toxicity or persistence of adverse effects observed during the dosing phase.
The animals received the test item, dissolved in Polyethylene glycol (PEG) 400 in softened water (by reverse osmosis) - 1:1 v/v, at a constant volume of 10 mL/kg body weight as indicated in the scheme below.
Main groups
Group |
Treatment (mg/kg body weight/day) |
Number of animals |
1 |
0 |
10M+10F |
2 |
62.5 |
10M+10F |
3 |
250 |
10M+10F |
4 |
1000 |
10M+10F |
Recovery groups
Group |
Treatment (mg/kg body weight/day) |
Number of animals |
5 |
0 |
5M+5F |
6 |
1000 |
5M+5F |
Main groups
Males were treated for 2 weeks prior to pairing and during pairing with females until the day before necropsy, for approximately 6 weeks. Females were treated for 2 weeks prior to pairing, during pairing and throughout the gestation and lactation periods until Day 3post partum. The following investigations were performed in all groups: body weight, clinical signs (including neurotoxicity assessment, motor activity, grip strength and sensory reaction to stimuli), food consumption, oestrous cycle, mating performance, clinical pathology investigations (haematology and clinical chemistry), litter data, macroscopic observations, organ weights and histopathological examination.
Body weight, clinical signs and macroscopic observations of pups were also performed.
Recovery groups
Animals of the recovery groups were treated for 4 consecutive weeks and sacrificed after 3 weeks of recovery (Groups 5, 6).
The following parameters were evaluated in these animals: mortality, clinical signs (including neurotoxicity assessment, motor activity, grip strength and sensory reaction to stimuli), body weight, food consumption, clinical pathology investigations (haematology and clinical chemistry), macroscopic observations, organ weights and histopathological examination.
Results
No mortality in parental animals occurred throughout the study.
Staining of different regions of the body surface was the main clinical sign recorded during treatment and recovery period in all treated groups. At observation of the cage tray, green/orange staining was recorded in all treated groups during treatment. Moreover, treated animals of the recovery group (Group 6) showed green staining in the cage tray also during the recovery period. These discolorations were due to the colour of the test item and its properties as textile dyes.
Neurotoxicity assessment (removal of animals from the home cage and open arena) did not reveal changes attributable to the test item. No relevant differences in motor activity or sensory reactivity to stimuli were noted between control and treated groups.
In males, no relevant differences in body weight and body weight gain were recorded in treated groups when compared to controls. In females, statistically significant decreases in body weight and body weight gain were detected in the high dose group starting from the second week of treatment up to post partum period. No difference in body weight gain was recorded in animals of both sexes during the recovery phase.
Slight decrease in food consumption was recorded in high dose females starting from pairing up to post coitum period. No changes were noted in post partum period. No changes were noted in treated males during treatment. No differences were noted during the recovery period in both sexes.
In males, slight leucopenia was recorded in the high dose group. In addition, slight thrombocytosis was recorded in mid- and high dose groups, with no dose-relation. In females, increase of reticulocytes was detected in the high dose group. These changes were not considered adverse due to the absence of changes in the other blood cell parameters and histopathology. Changes recorded at the coagulation test in mid-dose males and mid- and high dose females were considered of no toxicological relevance. No differences that could be considered treatment-related were detected in the recovery groups, confirming complete reversibility.
In females, relevant changes of liver/cholestasis markers were recorded in 2 out of 5 animals of the high dose group. The above findings could reflect liver impairment/cholestasis, even though changes were not confirmed at histopathological examination. Due to the limited incidence, it is unlikely that changes are treatment-related. In addition, a slight increase of creatinine was recorded in almost all females of the same group. In males, a decrease of liver markers and urea and an increase of total bilirubin and bile acids – which were due to an interference of the dye with the photometric measurement – were the most changes detected in the high dose group. Considering the severity and/or the direction of the findings observed in males were not considered to be suggestive of tissue/organ injury. In the recovery groups, changes recorded during the dosing phase completely recovered.
No significant differences in terminal body weight were noted between controls and treated animals, both in main and recovery groups. The most relevant change noted in the absolute and/or relative organ weight, between treated and control groups, was the increase of thyroid weights in high dose females (main and recovery groups) and the increase of liver weights in high dose males. In addition, a decrease in thymus weights was also detected in high dose females.
The most remarkable changes observed at post mortem examination in treated main group animals, when compared with controls, were reduced size of the thymus in most females dosed at 1000 mg/kg body weight/day and dark staining on the tail, on the dorsum of the skin or on the head. Such staining was considered related to the colour of the test item. In recovery animals, the only relevant changes noted at post mortem examination in treated animals, when compared with controls, were dark staining of the tail.
Treatment-related changes were noted in the thymus of most treated females dosed at > 250 mg/kg body weight/day, sacrificed at the end of treatment period. The incidence of this change was statistically significant in the high dose females with respect to controls. No histopathological changes were noted in the high dose females sacrificed after 3 weeks of recovery period or in females dosed at 62.5 mg/kg body weight/day. The histopathological change detected in the thymus was atrophy, represented by: a minimal to moderate reduction in cortical lymphocytes, shrinkage of the thymic lobules, increased prominence of interlobular septae and an inverse cellular density ratio cortex/medulla. In addition, in some instances, an increased number of apoptotic bodies “tingible body macrophages” was also reported. In control and high dose males, seminiferous tubules were evaluated with respect to their stage in the spermatogenic cycle and no alterations were noted.
Based on the results of the present study, the NOAEL (No Observed Adverse Effect Level) for general toxicity was considered to be 250 mg/kg body weight/day for female rats and 1000 mg/kg body weight/day for male rats.
Justification for classification or non-classification
The NOAEL is 250 mg/kg bw/day (oral). No target organ toxicity or specific toxic effects were observed. No classification applies.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.